Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
出版年份 2023 全文链接
标题
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
作者
关键词
-
出版物
Gynecologic Oncology
Volume 178, Issue -, Pages 119-129
出版商
Elsevier BV
发表日期
2023-10-19
DOI
10.1016/j.ygyno.2023.09.012
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
- (2022) Razvan Cristescu et al. Journal for ImmunoTherapy of Cancer
- Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
- (2022) Joaquim Bellmunt et al. CLINICAL CANCER RESEARCH
- Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
- (2022) Robert I Haddad et al. Journal for ImmunoTherapy of Cancer
- Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study
- (2022) Irene M. Shui et al. Journal for ImmunoTherapy of Cancer
- Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)
- (2021) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
- (2021) Razvan Cristescu et al. CLINICAL CANCER RESEARCH
- 338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study
- (2021) Peter Schmid et al. Journal for ImmunoTherapy of Cancer
- ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells
- (2020) Latika Singh et al. MOLECULAR CANCER RESEARCH
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
- (2019) Mary L. Disis et al. JAMA Oncology
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study
- (2019) U A Matulonis et al. ANNALS OF ONCOLOGY
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†
- (2019) N Colombo et al. ANNALS OF ONCOLOGY
- Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells
- (2019) Lihua Chen et al. CELLULAR ONCOLOGY
- Myeloid-derived suppressor cells coming of age
- (2018) Filippo Veglia et al. NATURE IMMUNOLOGY
- Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
- (2018) Christopher Groth et al. BRITISH JOURNAL OF CANCER
- Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028
- (2018) Andrea Varga et al. GYNECOLOGIC ONCOLOGY
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- The Glycolytic Switch in Tumors: How Many Players Are Involved?
- (2017) Li Yu et al. Journal of Cancer
- Anticancer strategies based on the metabolic profile of tumor cells: therapeutic targeting of the Warburg effect
- (2016) Xi-sha Chen et al. ACTA PHARMACOLOGICA SINICA
- Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
- (2015) C. Gebhardt et al. CLINICAL CANCER RESEARCH
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
- (2013) Christiane Meyer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor glycolysis as a target for cancer therapy: progress and prospects
- (2013) Shanmugasundaram Ganapathy-Kanniappan et al. Molecular Cancer
- Anticancer Agents That Counteract Tumor Glycolysis
- (2012) Carlotta Granchi et al. ChemMedChem
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started